首页> 美国卫生研究院文献>Oncotarget >PTEN expression is a prognostic marker for patients with non-small cell lung cancer: a systematic review and meta-analysis of the literature
【2h】

PTEN expression is a prognostic marker for patients with non-small cell lung cancer: a systematic review and meta-analysis of the literature

机译:PTEN表达是非小细胞肺癌患者的预后标志物:文献的系统评价和荟萃分析

代理获取
本网站仅为用户提供外文OA文献查询和代理获取服务,本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文,但由于OA文献来源多样且变更频繁,仍可能出现获取不到、文献不完整或与标题不符等情况,如果获取不到我们将提供退款服务。请知悉。

摘要

Phosphatase and tensin homolog deleted on chromosome 10 (PTEN) is a known tumor suppressor in non-small cell lung cancer (NSCLC). By performing a systematic review and meta-analysis of the literature, we determined the prognostic value of decreased PTEN expression in patients with NSCLC. We comprehensively and systematically searched through multiple online databases up to May 22, 2016 for NSCLC studies reporting on PTEN expression and patient survival outcome. Several criteria, including the Newcastle-Ottawa Quality Assessment Scale (NOS), were used to discriminate between studies. In total, 23 eligible studies with a total of 2,505 NSCLC patients were included in our meta-analysis. Our results demonstrated that decreased expression of PTEN correlated with poor overall survival in NSCLC patients and was indicative of a poor prognosis for disease-free survival and progression-free survival in patients with NSCLC.
机译:在10号染色体上缺失的磷酸酶和张力蛋白同源物(PTEN)是非小细胞肺癌(NSCLC)中已知的肿瘤抑制因子。通过对文献进行系统的回顾和荟萃分析,我们确定了NSCLC患者PTEN表达降低的预后价值。截至2016年5月22日,我们通过多个在线数据库全面系统地搜索了NSCLC研究,这些研究报告了PTEN表达和患者生存结局。包括纽卡斯尔-渥太华质量评估量表(NOS)在内的多个标准用于区分研究。我们的荟萃分析总共包括23项合格研究,共计2,505名NSCLC患者。我们的结果表明,PTEN表达降低与NSCLC患者的总体生存率低相关,并且预示着NSCLC患者的无疾病生存期和无进展生存期预后不良。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
代理获取

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号